← All trials
NCT04834557
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 31, 2021
- Primary completion
- Nov 30, 2021
- Completion date
- Jan 31, 2022
- First posted
- Apr 8, 2021
- Last posted
- Jun 16, 2021
- Enrollment
- 90
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Tanta UniversityLead sponsor
- Tanta UniversityReponsible party - principal investigator
- Sinai UniversityOverall official - principal investigator
- Menoufia UniversityStudy director
- Tanta UniversityStudy director
- Tanta UniversityStudy chair
- Al Azhar UniversityStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.